Aspire Biopharma Holdings, Inc.
Nasdaq · CIK 0001847345 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$28,353
Cost Of Revenue
$22,603
Gross Profit
$5,750
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $28,353 | - | - |
| Cost Of Revenue | $22,603 | - | - |
| Gross Profit | $5,750 | - | - |
| Operating Income | $-1.6M | - | - |
| Net Income | $-3.2M | - | - |
| Eps Basic | -20.57 | - | - |
| Eps Diluted | -20.57 | - | - |
| Cash And Equivalents | $5.9M | - | - |
| Total Assets | $7.1M | - | - |
| Total Liabilities | $3.2M | - | - |
| Shareholders Equity | $3.9M | - | - |
| Operating Cash Flow | $-3.0M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Aspire Biopharma Holdings, Inc. | 2026-05-15 | 0001493152-26-023802 |
| S-1/A | Aspire Biopharma Holdings, Inc. | 2026-04-10 | 0001493152-26-016123 |
| 10-K/A | Aspire Biopharma Holdings, Inc. | 2026-04-08 | 0001493152-26-015737 |
| 10-K | Aspire Biopharma Holdings, Inc. | 2026-03-30 | 0001493152-26-013682 |
| 10-Q/A | Aspire Biopharma Holdings, Inc. | 2025-11-14 | 0001493152-25-023619 |
| 10-Q | Aspire Biopharma Holdings, Inc. | 2025-11-14 | 0001493152-25-022595 |
| 10-Q | Aspire Biopharma Holdings, Inc. | 2025-08-13 | 0001641172-25-023573 |
| 10-Q/A | Aspire Biopharma Holdings, Inc. | 2025-08-13 | 0001641172-25-023566 |